Ewing Sarcoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Patient Pool, Prevalence and Companies DelveInsight

Ewing Sarcoma Companies are Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Inc., Bristol-Myers Squibb, Ono Pharmaceuticals, Nektar Therapeutics, Inhibrx, Inc., and others.
(New York, USA) DelveInsight's "Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Ewing Sarcoma, historical and forecasted epidemiology as well as the Ewing Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Ewing Sarcoma market report provides current treatment practices, Ewing Sarcoma emerging drugs, Ewing Sarcoma market share of the individual therapies, current and forecasted epidemiology in 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan from 2020 to 2034. Ewing Sarcoma Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities.

Request for sample page @ [https://www.delveinsight.com/report-store/ewing-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Takeaways from the Ewing Sarcoma Market Report

* According to DelveInsight, Ewing Sarcoma market is expected to grow at a decent CAGR by 2034.

* The total Ewing Sarcoma Market Size in the 7MM is approximately USD 30 million in 2023 and is projected to increase during the forecast period (2024-2034).

* The leading Ewing Sarcoma Companies include Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Inc., Bristol-Myers Squibb, Ono Pharmaceuticals, Nektar Therapeutics, Inhibrx, Inc., and others.
* Promising Ewing Sarcoma Pipeline Therapies include Vigil EWS, Eribulin mesylate, Seclidemstat, SM-88, Lurbinectedin, CP-751,871, Abemaciclib, CLR 131, VAL-413, TP-1287, Nivolumab, Bempegaldesleukin, INBRX-109, and others
* According to DelveInsight's analysis, men are more frequently effected than women (with 3:2), in case of Ewing Sarcoma.
* Additionally, more than 80% of Ewing's sarcomais attributed to bone, often in femur, pelvis, ribsetc. Extra-osseous affects the soft tissues aroundthe bones, such as cartilage or muscle.
* On November 12, 2024, Actuate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to elraglusib, a novel glycogen synthase kinase-3 beta (GSK-3) inhibitor, for the treatment of Ewing sarcoma (EWS).
* On November 12, 2024, the FDA granted rare pediatric disease designation to elraglusib (9-ING-41), a novel GSK-3 inhibitor, as a potential treatment for patients with Ewing sarcoma.

Ewing Sarcoma Overview

Ewing sarcoma is a rare and aggressive cancer that primarily affects the bones or the soft tissues surrounding bones. It most commonly occurs in children, adolescents, and young adults, with peak incidence between ages 10 and 20. The most frequent sites of occurrence include long bones like the femur, pelvis, ribs, and scapula.

The exact cause of Ewing sarcoma is unknown, but it is associated with specific genetic changes, most commonly a translocation between the EWSR1 gene on chromosome 22 and the FLI1 gene on chromosome 11. This fusion gene leads to uncontrolled cell growth.

Symptoms include localized pain and swelling, often worse at night, and can be accompanied by fever, fatigue, and unintentional weight loss. In advanced stages, the cancer may spread to other parts of the body, such as the lungs, bone marrow, or other bones. Diagnosis involves imaging studies (X-ray, MRI, or CT scans), biopsy for histological examination, and genetic testing to confirm the diagnosis.

Treatment typically combines chemotherapy, surgery, and/or radiation therapy. Multimodal therapy aims to eradicate the primary tumor and any metastases. While advancements in treatment have improved survival rates, early diagnosis and comprehensive care are critical to achieving favorable outcomes in Ewing sarcoma.

To know more about Ewing's sarcoma treatment, visit @ Ewing Sarcoma Treatment Market [https://www.delveinsight.com/sample-request/ewing-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Recent Developmental Activities in the Ewing Sarcoma Treatment Landscape

* Vigil (Gradalis) is a fully personalized cellular immunotherapy being examined for the treatment of advanced cancers with major focus on recurrent or refractory Ewing's sarcoma. Vigil combines genetic engineering with immuno-oncology to stimulate an immune response against cancer cells. The cells from the tumor are genetically modified in two ways. First, the cells are modified to inhibit the production of furin protein that makes it difficult for the immune system to detect cancer cells. Second, cells are modified to produce granulocyte macrophage colony-stimulating factor (GM-CSF). Phase I study revealed clinical benefit with a median survival of two years. While the median OS of patients in the Phase II study, treated with the combination of Vigil, Irinotecan, and Temozolomide was not met; however, favorable eventfree survival was observed. It is currently under phase III trial and the estimated completion date of this study is December 2022.
* Eribulin mesylate (Eisai) is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action and inhibit the growth phase of microtubule dynamics, with increased vascular perfusion and permeability in tumor cores. It is currently under phase II trial for Ewing Sarcoma. In pre-clinical studies, eribulin showed broad-spectrum cytotoxicity and had low IC50 values when tested using a large panel of cancer cell lines. This investigational molecule has completed Phase II trial an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), or Ewing sarcoma (EWS) in January 2022.
* SM-88 (Tyme) is a novel, oral, investigational agent evaluated as maintenance therapy in combination with methoxsalen, phenytoin. SM88 is an exclusive dysfunctional tyrosine derivative and is the backbone of SM-88 used with MPS. It is designed to be absorbed by the cancer cell as if it were a functional tyrosine, but after uptake it interrupts the processes of protein synthesis, with key targeting of mucin 1. it is currently under phase II trial for Ewing Sarcoma and the estimated completion of this study is by 2022.
* Seclidemstat (Salarius Pharmaceuticals) is a small molecule designed to inhibit lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme regulating gene expression. LSD1 has been implicated in various types of cancer, with higher levels of LSD1 associated with poor patient prognosis. Seclidemstat (SP 2577) has been shown to inhibit LSD1's demethylation and scaffolding properties and has demonstrated potent therapeutic activity in preclinical models of Ewing sarcoma, a rare pediatric/adolescent bone cancer. It is currently under Phase I clinical trial and the expected completion date of this study in September 2023.

Ewing Sarcoma Epidemiology Segmentation in the 7MM

* Ewing Sarcoma Incident Cases
* Ewing Sarcoma Subtype-specific Cases
* Ewing Sarcoma Age-Specific Cases
* Ewing Sarcoma Gender-Specific Cases

Download the report to understand which factors are driving Ewing Sarcoma epidemiology trends @ [https://www.delveinsight.com/report-store/ewing-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Ewing Sarcoma Market Insights

The overall improvement in outcome of ES has been made through the tremendous efforts of researcher, clinicians all over the world, better liaison between all the stakeholders of treating team, and collaborative international research in a huge number of cases. The main challenge now remains in preventing recurrence, preventing drug resistance, reducing therapy related long-term toxicities and improving outcome in those with metastatic and relapsed/recurrent disease.

Ewing's Sarcoma Market Dynamics

The dynamics of Ewing Sarcoma market is expected to change due to the improvement in the diagnosis, incremental healthcare expenditure across the world and expected launch of emerging therapies during the forecast period of 20222034. Companies all over the globe are persistently working towards the development of new treatment therapies and some of the key players at the global level are Tyme, Gradalis, Oncurious, Eisai, and others.

Ewing Sarcoma Market Landscape

Anticipated launch of therapies such as Vigil, Eribulin mesylate is expected to fuel the growth of the market during the forecast period, i.e., 2022-2034. Widespread research and developmental activities of pharmaceutical companies, along with rising incidence will further fuel the growth of the market.

Learn more about the FDA-approved drugs for Ewing Sarcoma @ Ewing Sarcoma Therapies and Medication [https://www.delveinsight.com/sample-request/ewing-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Ewing Sarcoma Market Report

* Coverage- 7MM
* Ewing Sarcoma Companies- Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Inc., Bristol-Myers Squibb, Ono Pharmaceuticals, Nektar Therapeutics, Inhibrx, Inc., and others
* Ewing Sarcoma Pipeline Therapies- Vigil EWS, Eribulin mesylate, Seclidemstat, SM-88, Lurbinectedin, CP-751,871, Abemaciclib, CLR 131, VAL-413, TP-1287, Nivolumab, Bempegaldesleukin, INBRX-109, and others
* Ewing Sarcoma Market Dynamics: Ewing Sarcoma Market Drivers and Barriers
* Ewing Sarcoma Market Access and Reimbursement, Unmet Needs, and Emerging Drugs

Discover more about Ewing Sarcoma Drugs in development @ Ewing Sarcoma Clinical Trials [https://www.delveinsight.com/sample-request/ewing-sarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Content

* Key Insights
* Executive Summary of Ewing Sarcoma
* Competitive Intelligence Analysis for Ewing Sarcoma
* Ewing Sarcoma: Market Overview at a Glance
* Ewing Sarcoma: Disease Background and Overview
* Ewing Sarcoma Patient Journey
* Ewing Sarcoma Epidemiology and Patient Population
* Treatment Algorithm, Current Treatment, and Medical Practices
* Ewing Sarcoma Unmet Needs
* Key Endpoints of Ewing Sarcoma Treatment
* Ewing Sarcoma Marketed Products
* Ewing Sarcoma Emerging Therapies
* Ewing Sarcoma: Seven Major Market Analysis
* Attribute analysis
* 7MM: Ewing Sarcoma Market Outlook
* Access and Reimbursement Overview of Ewing Sarcoma
* KOL Views
* Ewing Sarcoma Market Drivers
* Ewing Sarcoma Market Barriers
* Appendix
* DelveInsight Capabilities
* Disclaimer
* About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ewing-sarcoma-treatment-market-2034-clinical-trials-ema-pdma-fda-approvals-medication-therapies-patient-pool-prevalence-and-companies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services



This release was published on openPR.